Evidence map›Paper›PMID 36841866›Full record

ArticleEye (London, England)2023

Relation of interdigitation zone changes and right-angle vessels in Macular Telangiectasia Type-2 (MacTel).

Kiran Chandran, Anantharaman Giridhar, Mahesh Gopalakrishnan, Sobha Sivaprasad

Open access · greenAbstract readComment
In one paragraph

Article in Eye (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Macular telangiectasia type 2: An update.The Journal of international medical research · 2026
    Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Kiran ChandranDepartment of Vitreoretinal Services, Giridhar Eye Institute, Cochin, Kerala, India.ORCID 0000-0002-5800-6670
Anantharaman GiridharDepartment of Vitreoretinal Services, Giridhar Eye Institute, Cochin, Kerala, India. giridhareye@gmail.com.ORCID 0000-0002-7126-4885
Mahesh GopalakrishnanDepartment of Vitreoretinal Services, Giridhar Eye Institute, Cochin, Kerala, India.
Sobha SivaprasadNIHR Biomedical Research Centre, Moorfields Eye Hospital, NHS Foundation Trust, London, UK.ORCID 0000-0001-8952-0659
Chaithanya Eye Hospital and Research Institute · INCommunity Eye Care Foundation · INMoorfields Eye Hospital NHS Foundation Trust · GB

Funding

Medical Research Council MR/P027881/1
6 · The paper itself

Abstract

backgroundTo study the relation between interdigitation zone (IDZ) and right-angle vessel (RAV) in Macular Telangiectasia Type-2 (MacTel).

methodsA total of 43 eyes of 38 patients with presence of definite RAV on colour fundus photograph (Gass and Blodi-only stage-3) were confirmed on multimodal imaging. The relation of IDZ changes and associated ellipsoid zone (EZ) alterations on spectral-domain optical coherence tomography (OCT) with RAV were studied at baseline and these OCT changes were followed up in 15 eyes over a mean of 3.86 years.

resultsA total of 58 RAVs were found in the 43 eyes and 53/58 (91.3%) RAVs were associated with IDZ alterations in 39 eyes. On follow-up, IDZ attenuation progressed to IDZ loss and subsequent EZ attenuation and loss. A pre-existing IDZ loss was associated with subsequent EZ defect (P = 0.002). In 36 eyes that had OCT angiography, eyes with RAV showed deep capillary plexus telangiectasia in all 36 (100%) eyes and 32/36 (89%) eyes showed IDZ changes with or without EZ loss.

conclusionsIDZ attenuation and/or loss are associated with RAV and may serve as predictor of EZ loss in MacTel.

Indexed as

Macula LuteaRetinal TelangiectasisAngiographyFluorescein AngiographyHumansRetinal VesselsRetrospective StudiesTomography, Optical Coherence

Identifiers

PMID36841866
PMCPMC10516857
OpenAlexW4322008865

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.